Loading...
  • acute
  • DLT will be defined as a grade III or greater toxicity developing within 3 weeks of the T cell infusion, as graded by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4 or new development of grade II-IV acute GVHD within 3 weeks of the T cell infusion that requires treatment with systemic glucocorticosteroids. (clinicaltrials.gov)
  • Acute GVHD (aGVHD) usually occurs during the first three months following an allogeneic BMT. (clinicaltrials.gov)
  • tumor
  • Indeed, the anti-tumor effect of these cytoablative strategies is believed to be caused not only by direct effects on the malignant cells, but also in part by induction of new T cell responses, as T cells expand within the lymphopenic environment ( 9 ). (jimmunol.org)
  • METHODS
  • Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. (clinicaltrials.gov)
  • therapy
  • Evaluate changes in natural killer (NK) cell number and function, plasma cytokines, gene expression profile of peripheral blood, and plasma proteins via proteomics, before, during, and after lenalidomide and panobinostat therapy. (clinicaltrials.gov)
  • Differentiation therapy to reduce tumour load followed by milder chemotherapy provides an alternative approach. (hindawi.com)
  • Clinical
  • Clinical signs of CRS correlate with T-cell activation and high levels of cytokines, including interleukin 6 (IL-6). (medscape.com)